NEWARK, NJ, Oct 17, 2019 – New Jersey Innovation Institute (NJII), an NJIT Corporation, has announced that Haro Hartounian, Ph.D., NJII senior executive director, biotechnology and pharmaceutical innovation, will be addressing the World Congress of Regenerative Medicine and Stem Cell in Dalian, China, Nov. 1, 2019. Hartounian’s address will focus on the Cell and Gene Therapy Development Center currently under construction in Newark, N.J., and the range of innovative services the center will be providing to the biopharmaceutical and biotechnology industries.
The Cell and Gene Therapy Development Center is led by Hartounian, who brings more than 25 years of experience and leadership developing biopharmaceutical products. The center’s Cell Therapy Unit utilizes state-of-the-art equipment to develop cutting-edge products in a cost- and time-effective manner. The Gene Therapy Unit addresses several hurdles in viral vector manufacturing, including production challenges related to the use of adherent host cell lines, virus stability and limitations in virus characterization.
In addition to his role as director of the Cell and Gene Therapy Development Center, Hartounian is an adjunct associate professor in Columbia University’s Chemical Engineering Department. He was formerly the CEO and co-founder of DIAVACS, a clinical-stage biotechnology company whose mission is to treat autoimmune diseases, and he founded Allied Bioventures, a business advisory service working with companies in the life sciences industry.
Hartounian served as president and CEO of Vyteris, Inc. and was founder, director and CEO of Protagenic Therapeutics Inc., a biotechnology company created to develop treatments for neurological disorders. Hartounian was also co-founder, president and COO of Microislet, Inc., where he established Microislet as a major player in the field of cell therapy for treatment of Type 1 diabetes.